
DBD Stock Forecast & Price Target
DBD Analyst Ratings
Bulls say
Diebold Nixdorf Inc. reported a 8.1% quarter-over-quarter and 7.8% year-over-year growth in Retail revenues, totaling $255 million, alongside a notable expansion of gross margins by 100 basis points to 24.7%. The company is set to achieve a significant increase in free cash flow (FCF), with an expected rise to $205 million in 2025, compared to $109 million in 2024; Q3 2025 marked the first time it generated positive FCF for four consecutive quarters. Additionally, the robust growth in revenue is anticipated to contribute to notable year-over-year earnings per share (EPS) growth in 2026, along with targeted gross margin improvements that could enhance overall profitability.
Bears say
Diebold Nixdorf faces significant challenges that contribute to a negative outlook on its stock, primarily stemming from technological missteps and a failure to innovate, which could adversely impact both revenues and profitability. The company's Banking segment has exhibited declining gross margins, with a recent total of 26.8%, which reflects increased competitive pressures and potential difficulties in meeting its debt obligations. Additionally, uncertainties in the global trade environment, disruptions in supply chains, and lower-than-anticipated demand for upgrades and replacements further exacerbate the company's financial vulnerabilities.
This aggregate rating is based on analysts' research of Diebold Nixdorf Inc and is not a guaranteed prediction by Public.com or investment advice.
DBD Analyst Forecast & Price Prediction
Start investing in DBD
Order type
Buy in
Order amount
Est. shares
0 shares